Answers are grounded in this paper and cite their sources.
Imaging plays an essential role in the diagnosis, staging and treatment monitoring of cancer, and the number of radiological procedures performed on cancer patients has grown considerably over recent years. However, the types of imaging procedures used vary widely, and clinical practice rarely makes use of new advances in imaging techniques early in their development, so patients often do not benefit from them. One simulation-based analysis suggested that increased investment in imaging could yield important improvements in cancer management in countries of all incomes, and the return on that investment is predicted to be significantly larger than that achievable by investment in treatment alone 1 . The rationale for this prediction is that more effective use of medical imaging could facilitate earlier diagnosis and intervention, identify optimal treatments and improve monitoring of therapy, with earlier modification of ineffective but costly treatment regimens. Other key roles for medical imaging include surgical and radiotherapy planning, especially for treating larger masses that are intrinsically inhomogeneous. Given the generally low response rates of targeted therapies in a series of basket trials 2 , and the considerable number of targeted drugs in use that lack documented overall survival (OS) benefits 3 , it has become extremely important to use imaging to select appropriate treatments for individual patients. The increased appreciation of genetic and epigenetic intra-tumoral and inter-tumoral heterogeneity implies that targeted treatment decisions based only on a single core biopsy are inherently flawed. Multi-site sampling is usually not clinically viable, and alternatives such as sampling of plasma biomarkers (e.g. circulating tumour cells) are promising but have yet to be validated and incorporated into routine clinical practice 4 . Imaging is the only approach that can adequately sample all primary and metastatic tumours non-invasively, and the further development of methods to detect molecular heterogeneity, such as 89 Zr–Pertuzumab positron emission tomography (PET) 5 , to produce validated clinical tools that can guide treatment decisions is essential. However, despite the growth in the adoption of imaging technologies such as X-ray CT, MRI and PET in routine radiological practice, little use is currently made of the rich molecular, cellular, metabolic, microstructural or physiologic information potentially available from advanced multi-modal imaging techniques. In practice, there remain substantial obstacles to current imaging techniques achieving their full potential, which motivates this discussion of how to address these challenges.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: